Dietary Fish Protein in Subjects With Insulin Resistance
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of our research project is to determine the effects of fish protein, present in fish, on insulin sensitivity in insulin-resistant human individuals, and its mechanism of action on glucose metabolism. Our hypothesis is that fish protein improves insulin sensitivity, glucose tolerance and plasma lipid profile through an improvement in a primary defect in insulin signaling in overweight and insulin-resistant subjects.
| Condition | Intervention | Phase |
|---|---|---|
|
Insulin Resistance Type 2 Diabetes |
Behavioral: Cod protein NCEP-diet |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Assessment of Insulin Sensitivity in Insulin-Resistant Subjects Fed Fish Protein |
- Insulin sensitivity at 4 weeks
- Insulin signaling in skeletal muscle at 4 weeks
- plasma lipids and lipoproteins at 4 weeks
- plasma inflammatory markers at 4 weeks
- glucose tolerance at 4 weeks
| Estimated Enrollment: | 24 |
| Study Start Date: | February 2004 |
| Estimated Study Completion Date: | December 2005 |
Recent data show that cod protein prevents the development of insulin resistance in rats. Dietary fish protein may also enhance insulin sensitivity in overweight insulin-resistant subjects by improving a primary defect in insulin signaling to PI 3-kinase, leading to reduced activation of the downstream effectors Akt and PKC. To determine whether this is the case, we will study the effects of fish protein on insulin sensitivity in humans, and how it improves the ability of muscles to use glucose. Such studies will help to advise individuals with insulin resistance or type 2 diabetes about eating fish.
Eligibility| Ages Eligible for Study: | 35 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- overweight or obese (BMI between 25 and 40 kg /m2)
- waist circumference above 88 cm for women and 102 cm for men
- fasting plasma insulin above 90 pmol/L
- fasting plasma glucose below 7.0 mmol/L and 2-h plasma glucose below 11.1 mmol/L
Exclusion Criteria:
- Individuals with diagnosed diabetes or any chronic, metabolic or acute disease
- Individuals who had a major surgery within the last 3 months
- Individuals who had a significant weight loss (±10%) within the last 6 months
- Individuals taking any medication known to affect lipid or glucose metabolism
- Subjects with dietary incompatibility with fish consumption (allergy, intolerance or dislike) and/or calcium supplementation
- Smokers
Contacts and Locations| Canada, Quebec | |
| Laval University | |
| Quebec city, Quebec, Canada, G1K 7P4 | |
| Principal Investigator: | Helene Jacques, PhD | Laval University |
| Principal Investigator: | Andre Marette, PhD | Laval University |
| Principal Investigator: | Stanley J Weisnagel, MD / FRCPC | Laval University |
More Information
No publications provided by Laval University
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00400036 History of Changes |
| Other Study ID Numbers: | MOP-64443 |
| Study First Received: | November 14, 2006 |
| Last Updated: | November 14, 2006 |
| Health Authority: | Canada: Ethics Review Committee Canada: Canadian Institutes of Health Research |
Keywords provided by Laval University:
|
cod protein insulin sensitivity plasma lipids glucose tolerance |
plasma inflammatory markers skeletal muscle insulin signaling type 2 diabetes humans |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Insulin Resistance Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Hyperinsulinism Insulin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013